

Chlorpromazine (CPZ) SDS/MSDS (Safety Data Sheet)

1. PRODUCT AND COMPANY IDENTIFICATION

Product identifier

- * Product Name: Chlorpromazine (CPZ)
- * Catalog Number: S5749
- * CAS Number: 50-53-3
- * IUPAC Name: 10H-Phenothiazine-10-propanamine, 2-chloro-N,N-dimethyl-

Relevant identified uses and uses advised against

- * Identified uses: For research and development use only; laboratory chemicals; manufacture of substances.
- * Uses advised against: Not for pharmaceutical, household, or other unapproved uses.

Details of the supplier

- * Company: Selleck Chemicals
- * TollFree: +1 877 796-6397
- * Tel: +1 832 582-8158
- * Fax: +1 832 582-8590

Emergency telephone number

- * Emergency phone #: +1 832 582-8158

2. HAZARDS IDENTIFICATION

2.1 GHS classification in accordance with 29 CFR 1910 (OSHA HCS):

- Acute toxicity (oral): Category 3. H301
- Skin sensitization: Category 1. H317
- Acute toxicity (inhalation): Category 3. H331
- Reproductive toxicity: Category 1B. H362
- Acute aquatic toxicity: Category 1. H400
- Chronic aquatic toxicity: Category 1. H410

2.2 GHS Label elements, including precautionary statements

Hazard Pictogram(s)



Signal Word

Danger

Hazard statement(s)

- H301: Toxic if swallowed
- H317: May cause an allergic skin reaction
- H331: Toxic if inhaled
- H362: May cause harm to breast-fed children
- H400: Very toxic to aquatic life
- H410: Very toxic to aquatic life with long lasting effects

Precautionary statement(s)	None.
Prevention	<p>P203: Obtain, read and follow all safety instructions before use.</p> <p>P260: Do not breathe dust/fume/gas/mist/vapors/spray.</p> <p>P261: Avoid breathing dust/fume/gas/mist/vapors/spray.</p> <p>P263: Avoid contact during pregnancy/while nursing.</p> <p>P264: Wash hands thoroughly after handling.</p> <p>P270: Do not eat, drink or smoke when using this product.</p> <p>P271: Use only outdoors or in a well-ventilated area.</p> <p>P272: Contaminated work clothing should not be allowed out of the workplace.</p> <p>P273: Avoid release to the environment.</p> <p>P280: Wear protective gloves/protective clothing/eye protection/face protection/hearing protection.</p>
Response	<p>P301+P316: IF SWALLOWED: Get emergency medical help immediately.</p> <p>P302+P352: IF ON SKIN: wash with plenty of water.</p> <p>P304+P340: IF INHALED: Remove person to fresh air and keep comfortable for breathing.</p> <p>P316: Get emergency medical help immediately.</p> <p>P318: if exposed or concerned, get medical advice.</p> <p>P321: Specific treatment (see information on this label and safety datasheet)).</p> <p>P330: Rinse mouth.</p> <p>P333+P317: If skin irritation or rash occurs: Get medical help.</p> <p>P362+P364: Take off contaminated clothing and wash it before reuse.</p> <p>P391: Collect spillage.</p>
Storage	<p>P403+P233: Store in a well-ventilated place. Keep container tightly closed.</p> <p>P405: Store locked up.</p>
Disposal	P501: P501 Dispose of contents/ container to an approved waste disposal plant.

2.3 Other hazards

None.

3. COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Product name: Chlorpromazine (CPZ)

CAS Number: 50-53-3

PubChem CID: 2726

Molecular formula: C₁₇H₁₉CIN₂S

Molecular weight: 318.9 g/mol

IUPAC name: 3-(2-chlorophenothiazin-10-yl)-N,N-dimethylpropan-1-amine

3.2 Mixtures

Not applicable (pure substance).

4. FIRST-AID MEASURES

4.1 Description of first aid measures

Inhalation: Move to fresh air. Keep at rest in a position comfortable for breathing. Seek medical attention if symptoms persist.

Skin contact: Wash with plenty of soap and water. Remove contaminated clothing. Seek medical attention if irritation develops.

Eye contact: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do. Continue rinsing. Seek medical attention.

Ingestion: Rinse mouth. Do NOT induce vomiting unless directed by medical personnel. Seek medical attention.

4.2 Most important symptoms and effects, both acute and delayed

See Section 11 (Toxicological Information).

4.3 Indication of any immediate medical attention and special treatment needed

Treat symptomatically. Contact a poison control center or physician for severe exposure.

5. FIRE-FIGHTING MEASURES

5.1 Extinguishing media

Suitable: Water spray, dry chemical, carbon dioxide (CO₂), alcohol-resistant foam.

Unsuitable: None known.

5.2 Specific hazards arising from the substance or mixture

Water spray, dry chemical, carbon dioxide or foam as appropriate for surrounding fire and materials.

As with all fires, evacuate personnel to a safe area. Firefighters should use self-contained breathing equipment and protective clothing.

5.3 Advice for firefighters

Wear self-contained breathing apparatus (SCBA) and full protective clothing.

Fight fire from upwind. Cool containers with water spray until fire is extinguished.

6. ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

Wear appropriate personal protective equipment (see Section 8).

Avoid breathing dust/vapor. Ensure adequate ventilation.

Evacuate personnel to safe areas. Keep people away from and upwind of spill.

WARNING: Highly toxic — only trained personnel should handle spills.

6.2 Environmental precautions

Prevent product from entering drains, waterways, or soil.

Contain spill with inert absorbent material.

6.3 Methods and materials for containment and cleaning up

Wear approved respiratory protection, chemically compatible gloves and protective clothing. Wipe up spillage or collect spillage using a high efficiency vacuum cleaner. Avoid breathing dust. Place spillage in appropriately labeled container for disposal. Wash spill site.

SRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If

possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.

SRP: At the time of review, regulatory criteria for small quantity disposal are subject to significant revision, however, household quantities of waste pharmaceuticals may be managed as follows: Mix with wet cat litter or coffee grounds, double bag in plastic, discard in trash.

This material is assumed to be combustible. As with all dry powders it is advisable to ground mechanical equipment in contact with dry material to dissipate the potential buildup of static electricity.

As a general rule, when handling USP Reference Standards avoid all contact and inhalation of dust, mists, and/or vapors associated with the material. Wash thoroughly after handling.

SRP: Local exhaust ventilation should be applied wherever there is an incidence of point source emissions or dispersion of regulated contaminants in the work area. Ventilation control of the contaminant as close to its point of generation is both the most economical and safest method to minimize personnel exposure to airborne contaminants. Ensure that the local ventilation moves the contaminant away from the worker.

Use safety glasses or goggles and protect exposed skin.

SRP: The scientific literature for the use of contact lenses by industrial workers is inconsistent. The benefits or detrimental effects of wearing contact lenses depend not only upon the substance, but also on factors including the form of the substance, characteristics and duration of the exposure, the uses of other eye protection equipment, and the hygiene of the lenses. However, there may be individual substances whose irritating or corrosive properties are such that the wearing of contact lenses would be harmful to the eye. In those specific cases, contact lenses should not be worn. In any event, the usual eye protection equipment should be worn even when contact lenses are in place.

7. HANDLING AND STORAGE

7.1 Precautions for safe handling

Chlorpromazine hydrochloride oral solutions, tablets, and injection should be stored at a temperature less than 40 °C, preferably between 15-30 °C; freezing of the oral solutions and injection should be avoided. ... Chlorpromazine suppositories should be stored in well-closed containers between 15-30 °C. ...Chlorpromazine hydrochloride oral concentrate solution should be dispensed in amber glass bottles.

Store in tight, light-resistant container as defined in the USP-NF. This material should be handled and stored per label instructions to ensure product integrity.

7.2 Conditions for safe storage, including any incompatibilities

Chlorpromazine hydrochloride oral solutions, tablets, and injection should be stored at a temperature less than 40 °C, preferably between 15-30 °C; freezing of the oral solutions and injection should be avoided. ... Chlorpromazine suppositories should be stored in well-closed containers between 15-30 °C. ...Chlorpromazine hydrochloride oral concentrate solution should be dispensed in amber glass bottles.

Store in tight, light-resistant container as defined in the USP-NF. This material should be handled and stored per label instructions to ensure product integrity.

Store away from incompatible materials (see Section 10).

[Note: Specific storage temperature not available in public databases. Refer to supplier Certificate of Analysis (COA) for exact storage conditions.]

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 Exposure controls

8.1.1 Occupational exposure limits (OEL)

OSHA PEL: Not established.

ACGIH TLV: Not established.

NIOSH REL: Not established.

No occupational exposure limit values are established for this substance.

Use the lowest feasible exposure level (ALARA principle).

8.1.2 Appropriate engineering controls

Use only in a chemical fume hood or with local exhaust ventilation.

Ensure adequate ventilation to keep airborne concentrations below exposure limits.

8.2 Individual protection measures

8.2.1 Eye/face protection

Wear safety glasses with side shields.

8.2.2 Skin protection

Wear protective gloves. Recommended material: Nitrile rubber.

Wear suitable protective clothing (lab coat).

8.2.3 Respiratory protection

Wear NIOSH-approved respirator with appropriate cartridges. SCBA for high concentrations.

8.2.4 Thermal hazards

Not applicable.

9. PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties

- a) Appearance: Solid
- b) Odor: Amine odor
- c) Odor threshold: No data available
- d) pH: Alkaline reaction
- e) Melting point/freezing point: 177-178
- f) Initial boiling point and boiling range: 200-205 °C at 8.00E-01 mm Hg
- g) Flash point: No data available
- h) Evaporation rate: No data available
- i) Flammability (solid, gas): No data available
- j) Upper/lower flammability or explosive limits: No data available
- k) Vapor pressure: No data available
- l) Vapor density: No data available
- m) Relative density: No data available
- n) Water solubility: Very soluble in ethanol, ether, benzene and chloroform; soluble in dilute hydrochloric acid
- o) Partition coefficient: n-octanol/water: Log P (n-octanol/water): 5.2
- p) Auto-ignition temperature: No data available
- q) Decomposition temperature: No data available
- r) Viscosity: No data available
- s) Explosive properties: No data available
- t) Oxidizing properties: No data available

9.2 Other information

Topological Polar Surface Area (TPSA): 31.8 Å²

Complexity: 339

10. STABILITY AND REACTIVITY

10.1 Reactivity

No specific reactivity hazards identified under normal handling conditions.

10.2 Chemical stability

Stable under recommended storage conditions.

10.3 Possibility of hazardous reactions

No hazardous reactions under normal conditions.

10.4 Conditions to avoid

Avoid heat, sparks, open flames, direct sunlight, and moisture.

Avoid strong oxidizing agents, strong acids, and strong bases.

10.5 Incompatible materials

Chlorpromazine hydrochloride injection is physically and/or chemically incompatible with some drugs, but the compatibility depends on several factors (eg, concentrations of the drugs, specific diluents used, resulting pH, temperature). Specialized references should be consulted for specific compatibility information.

Oxidation of chlorpromazine hydrochloride occurs readily in alkaline media.

10.6 Hazardous decomposition products

Thermal decomposition may produce: Carbon monoxide (CO), Carbon dioxide (CO₂), Nitrogen oxides (NO_x), Sulfur oxides (SO_x), Hydrogen chloride (HCl).

See also Section 5 (Fire-fighting measures) for combustion products.

11. TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects

Acute toxicity:

No acute toxicity data available.

Skin corrosion/irritation:

No data available.

Serious eye damage/eye irritation:

No data available.

Respiratory or skin sensitization:

May cause an allergic skin reaction (H317).

Germ cell mutagenicity:

No data available.

Carcinogenicity:

No data available.

Reproductive toxicity:

No data available.

Specific target organ toxicity (single exposure):

No data available.

Specific target organ toxicity (repeated exposure):

No data available.

Aspiration hazard:

No data available.

11.2 Additional information

Carcinogen classification:

No indication of carcinogenicity to humans (not listed by IARC).

Exposure routes:

Oral, Intravenous.

Readily absorbed from the GI tract. Bioavailability varies due to first-pass metabolism by the liver.

Signs and symptoms of exposure:

Agitation, coma, convulsions, difficulty breathing, difficulty swallowing, dry mouth, extreme sleepiness, fever, intestinal blockage, irregular heart rate, low blood pressure, restlessness

Data source: Hazardous Substances Data Bank (HSDB) via PubChem.

12. ECOLOGICAL INFORMATION

12.1 Toxicity

Chlorpromazine's production and use as a medication may result in its release to the environment through various waste streams. If released to air, an estimated vapor pressure of 5.17×10^{-6} mm Hg at 25 °C indicates chlorpromazine will exist in both the vapor and particulate phases in the atmosphere. Vapor-phase chlorpromazine will be degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals; the half-life for this reaction in air is estimated to be 1.6 hours. Particulate-phase chlorpromazine will be removed from the atmosphere by wet or dry deposition. Chlorpromazine does not contain chromophores that absorb at wavelengths >290 nm, and therefore is not expected to be susceptible to direct photolysis by sunlight. If released to soil, chlorpromazine is expected to be immobile based upon an estimated Koc of 9,900. The pKa of chlorpromazine is 9.3, indicating that this compound will exist almost entirely in cation form in the environment and cations generally adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts. Volatilization from moist soil is not expected because the base exists as a cation and cations do not volatilize. If released into water, chlorpromazine is expected to adsorb to suspended solids and sediment based upon the estimated Koc. Biodegradation data were not available. The pKa indicates chlorpromazine will exist almost entirely in the cation form at pH values of 5 to 9 and therefore volatilize

12.2 Persistence and degradability

No data available.

12.3 Bioaccumulative potential

Log P (n-octanol/water): 5.2

Potential for bioaccumulation exists (Log P > 3).

12.4 Mobility in soil

No data available.

12.5 Results of PBT and vPvB assessment

PBT/vPvB assessment not available.

12.6 Other adverse effects

This substance is classified as hazardous to the aquatic environment.

13. DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods

Waste Treatment Methods: Waste material must be disposed of in accordance with national and local regulations. Leave chemicals in original containers and do not mix with other waste. Handle uncleaned containers in the same manner as the product itself.

14. TRANSPORT INFORMATION

14.1 UN number

Not regulated as dangerous goods (research quantities typically exempt).

14.2 UN proper shipping name

Not subject to transport regulations (small quantities for research use).

14.3 Transport hazard class(es)

Not classified as dangerous goods for transport (research quantities).

14.4 Packing group

Not applicable (not regulated as dangerous goods in typical research quantities).

14.5 Environmental hazards

Marine pollutant: Yes (classified as environmentally hazardous per GHS).

14.6 Special precautions for user

Transport in original packaging. Ensure containers are tightly sealed.

For bulk or commercial quantities, consult applicable transport regulations (DOT, IATA, IMDG).

14.7 Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable.

15. REGULATORY INFORMATION

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

US EPA / TSCA: Subject to EPA TSCA regulations

EU ECHA / REACH: Registered (REACH Active)

SARA 302 Components:

No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.

SARA 313 Components:

This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

SARA 311/312 Hazards:

Acute (short-term) health hazard
Chronic (long-term) health hazard
Environmental hazard

Massachusetts Right To Know Components:

This material contains components subject to the Massachusetts Right to Know Act. See Section 2 for hazard classification.

Pennsylvania Right To Know Components:

This material contains components subject to the Pennsylvania Right to Know Act. See Section 2 for hazard classification.

New Jersey Right To Know Components:

This material contains components subject to the New Jersey Right to Know Act. See Section 2 for hazard classification.

California Prop. 65 Components:

This product does not contain any chemicals known to the State of California to cause cancer, birth defects, or any other reproductive harm.

Other regulatory listings:

- FDA Requirements: The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, including chlorpromazine hydrochloride, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Chlorpr

15.2 Chemical safety assessment

A chemical safety assessment has not been carried out for this substance.
For research-use-only compounds, no CSA is required under REACH Annex I.

16. OTHER INFORMATION

Revision Date: 2026/09/09

Further Information: The information provided is believed to be correct but is not exhaustive and should be used only as a guideline based on current knowledge. It does not represent a guarantee of the properties of the product. Selleck Chemicals Corporation and its Affiliates shall not be held liable for any damage resulting from handling or contact with the product.